港股生物医药概念早盘跌幅居前，荣昌生物(09995.HK)跌超5%，药明合联(02268.HK)、药明生物(02269.HK)双双跌超4%，诺诚健华(09969.HK)，药明康德(02359.HK)等个股跟跌；消息面上，美国“大美丽法案”今日凌晨表决通过，法案提出削减医疗保健支出。

Group 1 - The Hong Kong stock market's biopharmaceutical sector experienced significant declines in early trading, with Rongchang Biopharmaceutical (09995.HK) dropping over 5% [1] - WuXi AppTec (02268.HK) and WuXi Biologics (02269.HK) both fell by more than 4% [1] - Other companies such as Innovent Biologics (09969.HK) and WuXi AppTec (02359.HK) also saw declines [1] Group 2 - The decline in the biopharmaceutical sector is attributed to the passage of the "Big Beautiful Act" in the U.S., which proposes cuts to healthcare spending [1]